ClinicalTrials.gov
public full text
Public Domain
Combination Therapy of Omalizumab and Allergen Immunotherapy for Moderate to Severe Asthma
The combined treatment of anti-IgE monoclonal antibody and standardized allergen immunotherapy has good efficacy and safety in allergic diseases. However, the efficacy and safety of the combined treatment for allergic asthma in the Chinese population have not been fully elucidated yet.This study is a prospective observational study designed to evaluate the efficacy and safety of omalizumab combined with allergen immunotherapy (AIT) in patients with moderate to severe asthma in the Chinese population.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Efficacy and Safety of OMT on Asthmatics#882930
- Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy#830591
- Effect of Anti-IgE in Non-Allergic Asthma#1030347
- Impact of Omalizumab on Corticosteroid Use, Emergency Room Visits and Hospitalizations#852694
- Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe Allergic Asthma#1172531
Record · ID 1059889
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive